Evidence map›Paper›PMID 33029356›Full record

ArticleMultiple sclerosis journal - experimental, translational and clinical

Anti-JCV antibody index does not change during ocrelizumab-treatment.

Torge Rempe, Aaron Carlson, Augusto Miravalle, Tirisham Victoria Gyang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Review
  3. Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients.Multiple sclerosis journal - experimental, translational and clinical
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Torge RempeDepartment of Neurology, College of Medicine, University of Florida, Gainesville, USA.ORCID https://orcid.org/0000-0003-0538-1378
Aaron CarlsonDepartment of Neurology, College of Medicine, University of Florida, Gainesville, USA.
Augusto MiravalleDepartment of Neurology, College of Medicine, University of Florida, Gainesville, USA.
Tirisham Victoria GyangDepartment of Neurology, College of Medicine, University of Florida, Gainesville, USA.ORCID https://orcid.org/0000-0002-6936-9186

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo prospectively assess anti-JCV antibody index (AI) and its relationship to immunoglobulin levels in ocrelizumab-treated MS patients.

methodsMonocentric prospective observational study over 24 months assessing anti-JCV AI and immunoglobulin levels in MS patients before and after initiation of ocrelizumab.

resultsNo significant change in anti-JCV AI titers was observed 458 ± 300 days after initiation of ocrelizumab (n = 45, 0.7 ± 2.21 vs. 0.6 ± 2.06, p = 0.8). Seroconversion occurred in 1/20 initially anti-JCV seronegative patients. There was no correlation between changes in anti-JCV AI and immunoglobulins.

conclusionTreatment with ocrelizumab is not associated with an increase in anti-JCV AI titers.

Indexed as

JCV antibody indexocrelizumabprogressive multifocal leukoencephalopathySTRATIFY JCV

Identifiers

PMID33029356
PMCPMC7522834

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.